Avanza Fonder AB Acquires New Holdings in Cerus Co. (NASDAQ:CERS)

Avanza Fonder AB purchased a new stake in Cerus Co. (NASDAQ:CERS) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 109,852 shares of the biotechnology company’s stock, valued at approximately $169,000.

Several other hedge funds also recently modified their holdings of CERS. Creative Planning increased its holdings in Cerus by 51.3% in the 3rd quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 8,411 shares in the last quarter. PCA Investment Advisory Services Inc. acquired a new position in shares of Cerus in the fourth quarter valued at approximately $46,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in Cerus by 38.4% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,074 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 9,737 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Cerus during the 3rd quarter worth approximately $71,000. Finally, Algert Global LLC bought a new stake in Cerus during the 2nd quarter worth approximately $97,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Price Performance

Cerus stock opened at $1.79 on Monday. The firm has a market cap of $332.42 million, a P/E ratio of -16.27 and a beta of 1.27. The stock’s 50 day moving average is $1.72 and its 200 day moving average is $1.89. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. Cerus Co. has a one year low of $1.38 and a one year high of $2.59.

Analyst Ratings Changes

Separately, Stifel Nicolaus cut their price target on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, October 17th.

Insider Transactions at Cerus

In other Cerus news, Director Eric Bjerkholt sold 20,000 shares of Cerus stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total value of $35,600.00. Following the completion of the sale, the director now directly owns 162,133 shares in the company, valued at approximately $288,596.74. The trade was a 10.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.40% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.